Sentinel node biopsy in breast cancer;La technique du ganglion sentinelle dans le cancer du sein: Quelques considérations récentes

Bulletin du Cancer

Volumn 96, Issue 6, 2009, Pages 713-725

  Hindie E ^a   Groheux, D ^a   Espie, M ^a   Bourstyn, E ^a   Toubert, M E ^a   Sarandi, F ^a   De Roquancourt, A ^a   Giacchetti, S ^a   Cuvier, C ^a   Cahen Doidy, L ^a   Teyton, P ^a   Misset, J L ^a   Maylin, C ^a   Moretti, J L ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

Breast cancer; Internal mammary node; Scintigraphy; Sentinel node; SPECT CT

Indexed keywords

ANTINEOPLASTIC AGENT; NANOCIS; NANOCOLL TC 99M; RHENIUM TECHNETIUM TC 99M; TRACER; UNCLASSIFIED DRUG; COLORING AGENT; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADJUVANT THERAPY; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CELL ISOLATION; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DRUG HYPERSENSITIVITY; HUMAN; ISOTOPE ANALYSIS; LENGTH OF STAY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHATIC DRAINAGE; LYMPHOSCINTIGRAPHY; MICROMETASTASIS; PREOPERATIVE EVALUATION; PROGNOSIS; RADIATION PROTECTION; REVIEW; SENTINEL LYMPH NODE BIOPSY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT INDICATION; TUMOR CELL; TUMOR VOLUME; ARTICLE; BREAST TUMOR; FEMALE; LYMPH NODE; LYMPHADENECTOMY; METHODOLOGY; PAGET NIPPLE DISEASE; PATHOLOGY; RECURRENT DISEASE; SCINTISCANNING; STANDARD;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; COLORING AGENTS; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; RADIATION PROTECTION; RADIOPHARMACEUTICALS; RECURRENCE; SENTINEL LYMPH NODE BIOPSY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 67651012591     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2009.0879     Document Type: Review

References (59)

1. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989 ; 63 : 181-187
2. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002 ; 20 : 3628-3636 (Pubitemid 34983222)
3. Michaelson JS, Silverstein M, Sgroi D, Cheongsiatmoy JA, Taghian A, Powell S, et al. The effect of tumor size and lymph node status on breast carcinoma lethality. Cancer 2003 ; 98 : 2133-2143 (Pubitemid 37392416)
4. Ivens D, Hoe AL, Podd TJ, Hamilton CR, Taylor I, Royle GT. Assessment of morbidity from complete axillary dissection. Br J Cancer 1992 ; 66 : 136-138
5. Singletary SE, Greene FL, Sobin LH. Classification of isolated tumor cells: clarification of the 6th edition of the American Joint Committee on Cancer Staging Manual. Cancer 2003 ; 98 : 2740-2741 (Pubitemid 37509544)
6. Bleiweiss IJ. Sentinel lymph nodes in breast cancer after ten years: rethinking basic principles. Lancet Oncol 2006 ; 7 : 686-692 (Pubitemid 44123580)
7. Lyman GH, Giuliano AE, Somerfield MR, Benson 3rd AB, Bodurka DC, Burstein HJ, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005 ; 23 : 7703-7720
8. Buscombe J, Paganelli G, Burak ZE, Waddington W, Maublant J, Prats E, et al. European Association of Nuclear Medicine Oncology Committee and Dosimetry Committee. Sentinel node in breast cancer procedural guidelines. Eur J Nucl Med Mol Imaging 2007 ; 34 : 2154-2159
9. Kim T, Giuliano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a meta-analysis. Cancer 2006 ; 106 : 4-16. (Pubitemid 43033320)
10. Masannat Y, Shenoy H, Speirs V, Hanby A, Horgan K. Properties and characteristics of the dyes injected to assist axillary sentinel node localization in breast surgery. Eur J Surg Oncol 2006 ; 32 : 381-384
11. Corone C. Ganglion sentinelle et cancer du sein. Médecine nucléaire-Imagerie fonctionnelle et métabolique 2004 ; 9 : 453-461
12. Mathelin C, Piqueras I, Guyonnet JL. Technologies en développement pour l'identification des ganglions sentinelles en chirurgie mammaire. Gynecol Obstet Fertil 2006 ; 34 : 521-525 (Pubitemid 43868127)
13. Nejc D, Wrzesien M, Piekarski J, Olszewski J, Pluta P, Kusmierek J, et al. Sentinel node biopsy in patients with breast cancer: evaluation of exposure to radiation of medical staff. Eur J Surg Oncol 2006 ; 32 : 133-138 (Pubitemid 43257111)
14. Viale G, Dell'Orto P, Biasi MO, Stufano V, De Brito Lima LN, Paganelli G, et al. Comparative evaluation of an extensive histopathologic examination and a real-time reverse-transcription-polymerase chain reaction assay for mammaglobin and cytokeratin-19 on axillary sentinel lymph nodes of breast carcinoma patients. Ann Surg 2008 ; 247 : 136-142
15. Wilke LG, McCall LM, Posther KE, Whitworth PW, Reintgen DS, Leitch AM, et al. Surgical complications associated with sentinel lymph node biopsy: results from a prospective International Cooperative Group trial. Ann Surg Oncol 2006 ; 13 : 491-500.
16. Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst 2006 ; 98 : 599-609 (Erratum in. J Natl Cancer Inst 2006; 98 : 876). (Pubitemid 43904843)
17. Zavagno G, De Salvo GL, Scalco G, Bozza F, Barutta L, Del Bianco P, et al. The GIVOM Trialists. A randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM Trial. Ann Surg 2008 ; 247 : 207-213
18. Bergkvist L, de Boniface J, Jönsson PE, Ingvar C, Liljegren G, Frisell J. Swedish society of breast surgeons. Axillary recurrence rate after negative sentinel node biopsy in breast cancer: three-year follow-up of the Swedish Multicenter Cohort Study. Ann Surg 2008 ; 247 : 150-156
19. de Kanter AY, Menke-Pluymers MM, Wouters MW, Burgmans I, van Geel AN, Eggermont AM. Five-year follow-up of sentinel node negative breast cancer patients. Eur J Surg Oncol 2006 ; 32 : 282-286
20. Cox C, White L, Allred N, Meyers M, Dickson D, Dupont E, et al. Survival outcomes in node-negative breast cancer patients evaluated with complete axillary node dissection versus sentinel lymph node biopsy. Ann Surg Oncol 2006 ; 13 : 708-711
21. Kuijt GP, van de Poll-Franse LV, Voogd AC, Nieuwenhuijzen GA, Roumen RM. Survival after negative sentinel lymph node biopsy in breast cancer at least equivalent to after negative extensive axillary dissection. Eur J Surg Oncol 2007 ; 33 : 832-837 (Pubitemid 47279045)
22. Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Ashikaga T, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol 2007 ; 8 : 881-888 (Pubitemid 47488052)
23. Goyal A, Newcombe RG, Chhabra A, Mansel RE, On behalf of the ALMANAC Trialists Group. Factors affecting failed localisation and false-negative rates of sentinel node biopsy in breast cancer - results of the ALMANAC validation phase. Breast Cancer Res Treat 2006 ; 99 : 203-208
24. Kim SC, Kim DW, Moadel RM, Kim CK, Chatterjee S, Shafir MK, et al. Using the intraoperative hand held probe without lymphoscintigraphy or using only dye correlates with higher sensory morbidity following sentinel lymph node biopsy in breast cancer: a review of the literature. World J Surg Oncol 2005 ; 3 : 64. (Pubitemid 41529239)
25. Lerman H, Lievshitz G, Zak O, Metser U, Schneebaum S, Even-Sapir E. Improved sentinel node identification by SPECT/CT in overweight patients with breast cancer. J Nucl Med 2007 ; 48 : 201-206 (Pubitemid 47555344)
26. Van der Ploeg IM, Valdés Olmos RA, Nieweg OE, Rutgers EJ, Kroon BB, Hoefnagel CA. The additional value of SPECT/CT in lymphatic mapping in breast cancer and melanoma. J Nucl Med 2007 ; 48 : 1756-1760 (Pubitemid 350099318)
27. Brenot-Rossi I, Houvenaeghel G, Jacquemier J, Bardou VJ, Martino M, Hassan-Sebbag N, et al. Non-visualization of axillary sentinel node during lymphoscintigraphy: is there a pathologic significance in breast cancer? J Nucl Med 2003 ; 44 : 1232-1237
28. de Kanter AY, Menke-Pluijmers MB, Henzen-Logmans SC, van Geel AN, van Eijck CJ, Wiggers T, et al. Reasons for failure to identify positive sentinel nodes in breast cancer patients with significant nodal involvement. Eur J Surg Oncol 2006 ; 32 : 498-501. (Pubitemid 43758432)
29. Maza S, Valencia R, Geworski L, Zander A, Guski H, Winzer KJ, et al. Peritumoural versus subareolar administration of technetium-99m nanocolloid for sentinel lymph node detection in breast cancer: preliminary results of a prospective intra-individual comparative study. Eur J Nucl Med Mol Imaging 2003 ; 30 : 651-656 (Pubitemid 36612945)
30. Rodier JF, Velten M, Wilt M, Martel P, Ferron G, Vaini-Elies V, et al. Prospective multicentric randomized study comparing periareolar and peritumoral injection of radiotracer and blue dye for the detection of sentinel lymph node in breast-sparing procedures: FRANSENODE trial. J Clin Oncol 2007 ; 25 : 3664-3669 (Pubitemid 47372605)
31. Heuts EM, van der Ent FW, von Meyenfeldt MF, Voogd AC. Internal mammary lymph drainage and sentinel node biopsy in breast cancer - a study on 1,008 patients. Eur J Surg Oncol 2009 ; 35 : 252-257
32. Anan K, Mitsuyama S, Kuga H, Saimura M, Tanabe Y, Suehara N, et al. Double mapping with subareolar blue dye and peritumoral green dye injections decreases the false-negative rate of dye-only sentinel node biopsy for early breast cancer: 2-site injection is more accurate than 1-site injection. Surgery 2006 ; 139 : 624-629 (Pubitemid 44269318)
33. Goyal A, Newcombe RG, Chhabra A, Mansel RE. Morbidity in breast cancer patients with sentinel node metastases undergoing delayed axillary lymph node dissection (ALND) compared with immediate ALND. Ann Surg Oncol 2008 ; 15 : 262-267
34. Husen M, Paaschburg B, Flyger HL. Two-step axillary operation increases risk of arm morbidity in breast cancer patients. Breast 2006 ; 15 : 620-628 (Pubitemid 44509772)
35. Knauer M, Konstantiniuk P, Haid A, Wenzl E, Riegler-Keil M, Postlberger S, et al. Multicentric breast cancer: a new indication for sentinel node biopsy: a multi-institutional validation study. J Clin Oncol 2006 ; 24 : 3374-3380 (Pubitemid 46638892)
36. van Rijk MC, Deurloo EE, Nieweg OE, Gilhuijs KG, Peterse JL, Rutgers EJ, et al. Ultrasonography and fine-needle aspiration cytology can spare breast cancer patients unnecessary sentinel lymph node biopsy. Ann Surg Oncol 2006 ; 13 : 31-35 (Pubitemid 43117642)
37. Wahl RL, Siegel BA, Coleman RE, Gatsonis CG, PET Study Group. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group. J Clin Oncol 2004 ; 22 : 277-285 (Pubitemid 41095092)
38. Veronesi U, De Cicco C, Galimberti VE, Fernandez JR, Rotmensz N, Viale G, et al. A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. Ann Oncol 2007 ; 18 : 473-478 (Pubitemid 46359625)
39. Groheux D, Hindié E, Espié M, Toubert ME, Misset JL, Giacchetti S, et al. Interests and perspectives of PET-CT for breast cancer: review of the literature. Bull Cancer 2007 ; 94 : 658-668 (Pubitemid 47413888)
40. van der Hoeven JJ, Krak NC, Hoekstra OS, Comans EF, Boom RP, van Geldere D, et al. 18F-2-fluoro-2-deoxy-d-glucose positron emission tomography in staging of locally advanced breast cancer. J Clin Oncol 2004 ; 22 : 1253-1259 (Pubitemid 41079839)
41. Groheux D, Moretti JL, Baillet G, Espie M, Giacchetti S, Hindié E, et al. Effect of (18)F-FDG PET/CT imaging in patients with clinical stage II and III breast cancer. Int J Radiat Oncol Biol Phys 2008 ; 71 : 695-704.
42. Van der Heiden-van der Loo M, Bezemer PD, Hennipman A, Siesling S, van Diest PJ, Bongers V, et al. Introduction of sentinel node biopsy and stage migration of breast cancer. Eur J Surg Oncol 2006 ; 32 : 710-714 (Pubitemid 44276004)
43. Madsen AH, Jensen AR, Christiansen P, Garne JP, Cold S, Ewertz M, et al. Does the introduction of sentinel node biopsy increase the number of node positive patients with early breast cancer? A population-based study form the Danish Breast Cancer Cooperative Group. Acta Oncol 2008 ; 47 : 239-247
44. Cox CE, Kiluk JV, Riker AI, Cox JM, Allred N, Ramos DC, et al. Significance of sentinel lymph node micrometastases in human breast cancer. J Am Coll Surg 2008 ; 206 : 261-268
45. Tan LK, Giri D, Hummer AJ, Panageas KS, Brogi E, Norton L, et al. Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-up. J Clin Oncol 2008 ; 26 : 1803-1809
46. de Mascarel I, MacGrogan G, Picot V, Mathoulin-Pelissier S. Prognostic significance of immunohistochemically detected breast cancer node metastases in 218 patients. Br J Cancer 2002 ; 87 : 70-74 (Pubitemid 34888606)
47. Van Zee KJ, Manasseh DM, Bevilacqua JL, Boolbol SK, Fey JV, Tan LK, et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol 2003 ; 10 : 1140-1151 (Pubitemid 40486808)
48. Alran S, De Rycke Y, Fourchotte V, Charitansky H, Laki F, Falcou MC, et al. Validation and limitations of use of a breast cancer nomogram predicting the likelihood of non-sentinel node involvement after positive sentinel node biopsy. Ann Surg Oncol 2007 ; 14 : 2195-2201 (Pubitemid 47174905)
49. Houvenaeghel G, Nos C, Mignotte H, Classe JM, Giard S, Rouanet P, et al. Micrometastases in sentinel lymph node in a multicentric study: predictive factors of non-sentinel lymph node involvement - Groupe des chirurgiens de la fédération des centres de lutte contre le cancer. J Clin Oncol 2006 ; 24 : 1814-1822.
50. Newman EL, Kahn A, Diehl KM, Cimmino VM, Kleer CA, Chang AE, et al. Does the method of biopsy affect the incidence of sentinel lymph node metastases? Breast J 2006 ; 12 : 53-57
51. Bleiweiss IJ, Nagi CS, Jaffer S. Axillary sentinel lymph nodes can be falsely positive due to iatrogenic displacement and transport of benign epithelial cells in patients with breast carcinoma. J Clin Oncol 2006 ; 24 : 2013-2018 (Pubitemid 46622109)
52. Intra M, Rotmensz N, Veronesi P, Colleoni M, Iodice S, Paganelli G, et al. Sentinel node biopsy is not a standard procedure in ductal carcinoma in situ of the breast: the experience of the European Institute of Oncology on 854 patients in ten years. Ann Surg 2008 ; 247 : 315-319 (Pubitemid 351156776)
53. Tunon-de-Lara C, Giard S, Buttarelli M, Blanchot J, Classe JM, Baron M, et al. Sentinel node procedure is warranted in ductal carcinoma in situ with high-risk of occult invasive carcinoma and micro-invasive carcinoma treated by mastectomy. Breast J 2008 ; 14 : 135-140 (Pubitemid 351341834)
54. Papa MZ, Zippel D, Kaufman B, Shimon-Paluch S, Yosepovich A, Oberman B, et al. Timing of sentinel lymph node biopsy in patients receiving neoadjuvant chemotherapy for breast cancer. J Surg Oncol 2008 ; 98 : 403-406
55. Classe JM, Bordes V, Campion L, Mignotte H, Dravet F, Leveque J, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of ganglion sentinelle et chimiotherapie neoadjuvante, a French prospective multicentric study. J Clin Oncol 2009 ; 27 : 726-732
56. Chen RC, Lin NU, Golshan M, Harris JR, Bellon JR. Internal mammary nodes in breast cancer: diagnosis and implications for patient management: a systematic review. J Clin Oncol 2008 ; 26 : 4981-4989
57. Veronesi U, Arnone P, Veronesi P, Galimberti V, Luini A, Rotmensz N, et al. The value of radiotherapy on metastatic internal mammary nodes in breast cancer. Results on a large series. Ann Oncol 2008 ; 19 : 1553-1560
58. Sarlos D, Frey LD, Haueisen H, Landmann G, Kots LA, Schaer G. Radioguided occult lesion localization (ROLL) for treatment and diagnosis of malignant and premalignant breast lesions combined with sentinel node biopsy: a prospective clinical trial with 100 patients. Eur J Surg Oncol 2009 ; 35 : 403-408
59. van Esser S, Hobbelink MG, Peeters PH, Buskens E, van der Ploeg IM, Mali WP, et al. The efficacy of "radio guided occult lesion localization" (ROLL) versus "wire-guided localization" (WGL) in breast conserving surgery for non-palpable breast cancer: a randomized clinical trial: ROLL study. BMC Surg 2008 ; 8 : 9. (Pubitemid 351793267)